Skip to main content
AT

AimMax Therapeutics, Inc.

The startup develops biopharmaceuticals through in-licensing and co-development, focusing on anti-inflammatory, anti-bacterial, and anti-infective medicines targeting resistant microorganisms. By addressing the growing issue of antibiotic resistance, the company enables healthcare professionals to effectively treat infections that are difficult to manage with existing therapies.

Durham, United StatesFounded 20165300+ followers
Updated 18 months ago

Funding

$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

ON
Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Features

  • The startup develops biopharmaceuticals through in-licensing and co-development, focusing on anti-inflammatory, anti-bacterial, and anti-infective medicines targeting resistant microorganisms. By addressing the growing issue of antibiotic resistance, the company enables healthcare professionals to effectively treat infections that are difficult to manage with existing therapies.
This profile is AI-generated and may contain inaccuracies.